Overlooked Soviet-era Miramistin has ‘enormous potential’ as antiseptic

Organisation: Position: Deadline Date: Location:

A little-known non-toxic antiseptic developed in the Soviet Union during the Cold War has enormous potential to beat common infections, say University of Manchester scientists. Miramistin, developed for the Soviet Space Programme and little known in the West, can inhibit or kill influenza A, human papilloma viruses that cause warts, coronaviruses, adenoviruses, and human immunodeficiency virus (HIV).

The potion is much less toxic to human cells than conventional antiseptics such as cyclohexamide and cetylpyridinium chloride, and is also biodegradable. It can be used against Candida and Aspergillus species, and also kills bacteria, including Stарhуlососсus, Proteus and Klebsiella as well as the bugs that cause syphilis and gonorrhoea.

Miramistin is still used in some of the former countries of the Soviet Bloc in hospitals and surgeries, mainly to treat to treat wounds and ulcers. However, it is barely known elsewhere and there is almost no mention of it in the English literature.

“Conventional antiseptics contaminate the environment because they are toxic to microbiota, fish, algae and plants,” said Professor David Denning from the University of Manchester, who was on the research team. “These are widely available but problematic whereas Miramistin has no genotoxic effects after it has been broken down.”

Widely used antiseptics with chlorinated aromatic structures including triclosan and triclocarban barely degrade and so persist in the environment for long significant periods, even decades. In contrast, Miramistin is 88–93% biodegradable

Lead author Dr Ali Osmanov, awarded a scholarship to study fungal disease at Manchester, examined Miramistin in the lab for his dissertation project. When in his native country, Ukraine, he discovered extensive clinical use of Miramistin, causing him to consider if it might be useful elsewhere.

He said: “Miramistin has been overlooked in the West and may have practical and environmental advantages. Today, antiseptics act as a ‘last frontier’ against antibiotic-resistant bacteria and viruses, and also have important role in infection control. Unfortunately, currently used antiseptics have some flaws. For example, bleach can exacerbate asthma, and many of the older antiseptics are not active against coronaviruses. We hope our paper will stimulate modern studies to evaluate Miramistin’s potential. Considering emerging antimicrobial resistance, the significant potential of miramistin justifies its re-evaluation for use in other geographical areas and conditions.”

Miramistin is a topical antiseptic with broad antimicrobial action, including activity against biofilms and a clinical profile showing good tolerability. Miramistin was developed within a framework of the Soviet Union Cold War Space Program. It is available for clinical use in several prior Soviet bloc countries, but barely known outside of these countries and there is almost no mention of miramistin in the English literature. However, considering emerging antimicrobial resistance, the significant potential of miramistin justifies its re-evaluation for use in other geographical areas and conditions. The review consists of two parts: (i) a review of the existing literature on miramistin in English, Russian and Ukrainian languages; (ii) a summary of most commonly used antiseptics as comparators of miramistin. The oral LD50 was 1200 mg/kg, 1000 mg/kg and 100 g/L in rats, mice and fish, respectively. Based on the results of the review, we suggest possible applications of miramistin and potential benefits over currently used agents. Miramistin offers a novel, low toxicity antiseptic with many potential clinical uses that need better study which could address some of the negative impact of antimicrobial, antiseptic and disinfectant resistance.

Ali Osmanov, Zara Farooq, Malcolm D Richardson, David W Denning


University of Manchester material


FEMS Microbiology Reviews abstract

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.